Should we enlarge the indication for kidney biopsy in patients with diabetes? The pro part.

"CONFLICT OF INTEREST STATEMENT L.G. received grant support from Abionyx and Sanofi to his university department (DIMEPRE-J); he has been a member of advisory boards for AstraZeneca, Baxter, Chinook, GSK, Mundipharma, Novartis, Pharmadoc, Roche, Sanofi, Travere and Vifor Pharma, and an invited speaker at meetings supported by AstraZeneca, Astellas, Estor, Fresenius, Werfen, Medtronic, Travere and GSK. P.P. has been a member of an advisory board for Sanofi and was an invited speaker at meetings supported by Werfen and Estor. M.F. has been an invited speaker at meetings supported by AstraZeneca, Bayer, Estor and bioMerieux."

"P.P. was supported by grant Horizon Europe Seeds from the University of Bari Aldo Moro (DETO S20 DKD Avatar). L.G. has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115974. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA with JDRF. CONFLICT OF INTEREST STATEMENT: L.G. received grant support from Abionyx and Sanofi to his university department (DIMEPRE-J); he has been a member of advisory boards for AstraZeneca, Baxter, Chinook, GSK, Mundipharma, Novartis, Pharmadoc, Roche, Sanofi, Travere and Vifor Pharma, and an invited speaker at meetings supported by AstraZeneca, Astellas, Estor, Fresenius, Werfen, Medtronic, Travere and GSK. P.P. has been a member of an advisory board for Sanofi and was an invited speaker at meetings supported by Werfen and Estor. M.F. has been an invited speaker at meetings supported by AstraZeneca, Bayer, Estor and bioMerieux."